The existence of two distinct antigenic sites at the surface of simian virus 40 (SV40)-transformed H-2b cells has been previously demonstrated (A. E. Campbell, L. F. Foley, and S. S. Tevethia, J. Immunol. 130:490-492, 1983) by using two independently isolated SV40-specific cytotoxic T-lymphocyte (CTL) clones, Kll and K19. We identified amino acids in the amino-terminal half of SV40 T antigen that are essential for the recognition of antigenic sites by these CTL clones by using H-2b cells transformed by mutants that produce T antigen truncated from the amino-terminal or carboxy-terminal end or carrying overlapping internal deletions in the amino-terminal regions of SV40 T antigen. The results show that CTL clone Kll failed to recognize and lyse target cells missing SV40 T-antigen amino acids 189 to 211, whereas CTL clone K19 lysed these cells. The cell lines missing SV40 T-antigen amino acids 220 to 223 and 220 to 228 were not lysed by CTL clone K19 but were susceptible to lysis by CTL clone Kll. Two other cell lines missing amino acids 189 to 223 and 189 to 228 of SV40 T antigen were not lysed by either of the CTL clones but were lysed by SV40-specific bulk-culture CTL if sufficient amounts of relevant restriction elements were expressed at the cell surface. The SV40 T-antigen amino acids critical for the recognition of an antigenic site by CTL clone Kll were identified to be 193 to 211; 220 to 223 were identified as critical for recognition by CTL clone K19. The deletion of these amino acids from the T antigen resulted in the loss of antigenic sites specific for CTL clones Kll and K19.
Simian virus 40 (SV40)-transformed and -infected cells synthesize a tumor-specific transplantation antigen expressed on the cell surface that induces the host immune response, resulting in tumor rejection (for reviews, see references 56 and 57). Mice immunized with SV40 or with syngeneic SV40-transformed cells develop cytotoxic T lymphocytes (CTL) that lyse SV40-transformed or -infected syngeneic cells in an H-2-restricted manner (17, 35, (42) (43) (44) and mediate tumor rejection in vivo (18) . It is now firmly established that the TSTA activity resides in a virus-encoded multifunctional protein of 94 kilodaltons (kDa), the large T antigen. T antigen purified to homogeneity immunizes mice against SV40 tumor transplantation (9, 58) and induces a cellular immune response in the immunized host (8, 58) . In addition, the T antigen provides a target recognized by SV40-specific CTL (41, 61) . Although the majority of T antigen is localized in the nucleus of SV40-transformed or -infected cells, a small amount can be demonstrated at the cell surface by various serological means (7, 11, 12, 27, 28, 38, 39, 46-48, 51, 52, 59) . Presumably, it is this surface T antigen that is recognized by CTL. SV40-specific monoclonal antibodies have identified multiple antigenic sites on the T antigen (3, 23, 26, 37) . However, at the cell surface, only selected portions of the T antigen are accessible to these monoclonal antibodies (3, 12, 20, 46, 68) . Similarly, antigenic sites recognized by CTL are present in both the amino-terminal and the carboxy-terminal halves of the T antigen. Mouse cells expressing either a 33-kDa amino-terminal T-antigen fragment (21, 61) or a 28-kDa carboxy-terminal fragment (21) contains an EcoRI linker between nucleotides 5194 and 5186 and includes the SV40 early-region promoter but not the initiation codon for the large T antigen. The nucleotide alterations in the mutants used in these constructions are shown in Fig. 1 . The first initiation codon in the reading frame of large T antigen within the TaqI-BamHI fragment occurs at methionine 109. The plasmid pPVU-5-70K contains the TaqIBamHI fragment derived from the mutant pPVU-5 (32) , which contains a 7-base-pair deletion (nucleotides 4527 to 4521) 5' to the first initiation codon. Based on nucleotide sequence, this plasmid is expected to produce a polypeptide consisting of amino acids 109 to 708.
The plasmid py2xmetl28-70K contains the TaqI-BamHI fragment of a mutant with an in-frame deletion (y2) of nucleotides 4501 to 4481 and a base change of A to T at nucleotide 4435. The y2 deletion removes the AUG codon for amino acid 109. The point mutation converts the lysine codon at position 128 to a methionine codon. The plasmid is expected to produce a T antigen consisting of amino acids 128 to 708. The plasmid py2xB9-70K contains a TaqI-BamHI fragment bearing the y2 deletion and a G-to-A transition at nucleotide 4370. The base change introduces an initiation codon at position 150. The T antigen produced from this plasmid should contain amino acids 150 to 708. The plasmid p60K, named for the expected molecular weight of its product, contains the TaqI-BamHI fragment from the mutant K2 (32) . The G-to-A transition in this mutant converts the methionine at 109 to isoleucine. The first available in-frame methionine codon in this construct corresponds to amino acid 176 in the T antigen.
The plasmids pH-2Kb and pH-2Db containing the murine major histocompatibility (MHC) class I genes Kb and Db (1, 22, 50) were kindly provided by H. Allen. The plasmid pSV2-neo contains the aminoglycosyl 2' phosphotransferase gene that confers on mammalian cells resistance to the antibiotic G418 and that has been described previously (53) .
Transfection and transformation of primary C57BL/6 mouse embryo fibroblasts with plasmid DNA. Primary C57BL/6 mouse embryo fibroblast cultures (B6/MEF) were prepared as described previously (55) (FCS) . After incubation at 37°C overnight, cells were transfected with 1 ,g of plasmid DNA and 10 ,ug of carrier DNA from B6/MEF in the form of a calcium phosphate precipitate. The transfected cells containing the precipitate were incubated for 16 h at 37°C, at which time the medium was replaced with fresh DMEM containing 10% FCS. The cultures were fed every third day for a period of 3 to 4 weeks. The individual colonies of transformed cells were picked and established as cell lines.
Cell lines. The cell lines used in this study, their origins, and H-2 haplotypes are listed in Table 3 . In addition to the cell lines generated after transformation of B6/MEF by the SV40 deletion mutants, B6/WT-19, an SV40-transformed cell line of B6 origin (59) , and a cell line (B6/PY) derived from a tumor induced by the polyomavirus (25) were also used. C3HSV-4 is an SV40-transformed cell line of C3H/HeJ (H-2k) origin. The cell lines of H-2k origin, L/pVBETK-1 and L/pVBtlTK-1, which synthesize a full-length T antigen and a 33-kDa amino-terminal fragment of T antigen, respectively, and LTK-have been described previously (45, 61) .
All the cell lines were maintained in DMEM containing either 10 or 5% FCS.
Expression of H-2Kb and H-2Db genes in L/pVBETK-1, L/pVBtlTK-l, and LTK-cells. Since L/pVBtlTK-1 cells, which synthesize an amino-terminal 33-kDa fragment of SV40 T antigen, are of H-2k origin and the CTL clones (Kl1 and K19) used to map the antigenic sites on T antigen are of H-2b origin, the L/pVBETK-1, L/pVBtlTK-1, and LTK- Generation of SV40-sensitized lymphocytes. SV40-sensitized lymphocytes were generated as previously described (15, 59 ). C57BL/6 mice were immunized intraperitoneally with 1 x 107 to 2 x 107 syngeneic SV40-transformed cells. After 9 or more days, the spleens were excised, and a single-cell suspension was prepared by pressing the spleens through a 60-gauge stainless steel screen. The splenic erythrocytes were removed by hypotonic lysis with Tris-ammonium chloride. Lymphocytes (1.5 x 107) were cocultured with 2 x 105 -y-irradiated (10,000 rads), syngeneic SV40-transformed stimulator cells in RPMI 1640 supplemented with 5 x 10-5 M ,-mercaptoethanol-25 p.g of pyruvate per ml-10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)-0.225% NaHCO3-100 U of penicillin per ml-100 ,ug of streptomycin per ml-0.03% glutamine-10% FCS heat inactivated at 56°C for 30 min. The cultures were maintained at 37°C in 5% CO2 for 5 days. The phenotype of the effector cells generated by this method is Thyl+ LytlLyt2+ (15) . SV40-specific CTL clones. CTL clones Kll and K19 are specific for the SV40 large T antigen and are H-2Db restricted (6) . Both of these CTL clones recognize antigenic determinants present on a truncated large T antigen of amino acid residues 1 to 368 (60) . CTL clone K19 cross-reacts with a large T antigen encoded by the human papovavirus BK, whereas the determinant recognized by Kll is found only on the SV40 large T antigen (6) .
Cytotoxicity assay. The 51Cr release assay was performed as previously described (15, 59 FACS analysis. To determine the surface expression of the host-encoded H-2 antigens, FACS analysis using monoclonal antibodies reactive with the H-2Kb and H-2Db antigens was performed on viable cells (31) . Cells for analysis were removed from the culture flasks by using EDTA and 0.1% trypsin and suspended with FACS buffer (phosphatebuffered saline [0.68% NaCl, 0.17% Na2HPO4, 0.02% KH2PO4, pH 7.4] with 2% FCS and 0.1% NaN3). The cells were diluted to 106/ml, and 1 ml was dispensed to glass culture tubes (12 by Table 4 show that the H-2 restriction and antigen specificity of these two clones were maintained during in vitro passage and that both CTL clones lysed SV40-transformed H-2b cells but not SV40-transformed H-2k cells or polyomavirus-transformed H-2b cells.
The results also show that as reported previously (6) carboxy-terminal end of the T antigen (M. Tevethia, unpublished data). These studies indicate that the epitopes recognized by the CTL clones Kll and K19 lie between amino acids 176 and 368 of the T antigen.
Localization of epitopes recognized by CTL clones Kll and K19 between amino acids 176 and 271 of the T antigen. To further narrow the region encompassing epitopes recognized by CTL clones Kll and K19, cell line L/pVBtlTK-1, which synthesizes a truncated T antigen of 1 to 271 residues was used (Fig. 3) . However, this cell line (45, 61) is of H-2k origin and was of an inappropriate haplotype for mapping CTL clones Kll and K19, which are of H-2b origin. We and others have previously shown that the L/pVBtlTK-1 cells possess epitopes that are recognized by the CTL generated in H-2k mice (21, 61) . Attempts to generate a transformed cell line of H-2b origin that synthesizes a stable truncated T antigen of 33 kDa had failed. Therefore, an alternate approach was undertaken in which the H-2b class I restricting elements, the cloned H-2Kb and H-2Db genes (1), were expressed in L/pVBtlTK-1 cells, so that they could provide the correct restriction element and allow these cells to be tested for reactivity against CTL clones Kll and K19. The H-2Kb and H-2Db genes were transfected into L/pVBtlTK-1 cells. In addition, L/pVBETK-1 cells, which produce a 94-kDa T antigen, and the parental LTK-cells were transfected with the H-2Kb and H-2Db genes to serve as positive and negative controls, respectively. Both of these cell lines are of H-2k origin (Fig. 3) . The expression of the transfected H-2b genes was determined by reacting the cells with monoclonal antibodies EH-144 (anti-H-2Kb) and 28-14-8 (anti-H-2Db) and analyzing these by FACS. The number of positive cells indicated on the vertical axis was plotted against the log fluorescence intensity on the horizontal axis (Fig. 4) To determine whether the CTL clones Kll and K19 recognized a determinant present within the sequence of amino acids 176 to 271, the cell lines indicated in Fig. 3 were reacted with CTL clones Kll and K19 at an effector-totarget-cell ratio of 10:1. The results are shown in Fig. 3 (Fig. SA) were transfected into syngeneic B6/MEF, and individual transformed cell lines were established and assayed for sensitivity to lysis by the CTL clones in a 51Cr release assay at an effector-to-target-cell ratio of 10:1. CTL clones Kl1 and K19 were first tested against the cell lines B6/RL5-S24 and B6/RL75-RL12, which produce T-antigen molecules missing residues 218 to 250 and residues 189 to 228, respectively (Fig. 5A) . The results are shown in Fig. 5B . Both CTL clones lysed B6/WT-19, the positive control, but not B6/PY, the negative control. The CTL clone K19 did not kill the cell line B6/RL5-S24 (missing residues 218 to 250), while Kll did (Fig. SB) . Neither CTL clone lysed the cell line B6/RL75-RL12, which is missing amino acids 189 to 228 (Fig. 5B ).
These data indicate that residues 189 to 228 are critical for recognition of antigenic sites by CTL clones Kll and K19, while residues 218 to 250 are essential for recognition of an antigenic site by CTL clone K19.
To identify the smallest possible deletion that could destroy CTL recognition, several additional deletion mutants missing amino acids ranging from residues 189 to 228 were chosen. Transformed cell lines were established and assayed for sensitivity to lysis by Kll and K19 in a 51Cr release assay at an effector-to-target-cell ratio of 10:1 (Fig. SC) K19 . The results of the preceding experiments showed that amino acids 189 to 211 are critical for the recognition of an antigenic site by CTL clone Kll, whereas amino acids 220 to 223 are critical for the recognition of an antigenic site by CTL clone K19. When cell lines expressing SV40 T antigen carrying a deletion of amino acids 189 to 228 (B6/RL75-RL12) or 189 to 223 (B6/RL75-RL115) were tested against CTL clones Kll and K19, they were found to be nonreactive in the 51Cr release assay in repeated experiments. Results obtained so far support the conclusion that deletions of amino acids 189 to 223 and 189 to 228 affect antigenic sites recognized by both the CTL clones (Kll and K19). For the mapping studies to be valid, it must be demonstrated that the mutant SV40 T antigen is expressed at the cell surface and is able to associate with class I antigens. Preliminary results indicate that the two cell lines B6/RL75-RL12 and B6/RL75-RL115 were not sensitive to lysis by a heterogeneous bulk culture of SV40-specific CTL generated in B6 mice by using syngeneic SV40-transformed cells carrying wild-type T antigen.
To determine whether a decreased level of H-2 expression is responsible for the inability of SV40-specific CTL to lyse B6/RL75-RL12 and B6/RL75-RL115 cells, and to finally confirm the CTL mapping studies described earlier, it was necessary to enhance the level of expression of the class I molecules. Treatment of cells with gamma interferon has been shown to enhance the expression of the MHC antigens (14, 16, 67) . In these experiments, the cells were treated with gamma interferon and first analyzed for the expression of the H-2b molecules and then for sensitivity to lysis by the CTL clones Kll and K19. B6/WT-19, B6/RL75-RL12 (missing residues 189 to 228), B6/RL75-RL115 (missing residues 189 to 223), and B6/PY were treated with 100 U of gamma interferon per ml of DMEM containing 10% FCS for 48 h, after which the medium was removed and fresh medium without gamma interferon was added for 12 h. Treated and untreated cells were analyzed for the expression of the H-2Kb and H-2Db molecules by flow cytometry (Fig. 6) . Untreated B6/RL75-RL12 and B6/RL75-RL115 cells showed a very low level of H-2Kb and H-2Db expression, while B6/WT-19 expressed a normal level. Treatment of these same cell lines with gamma interferon raised the percentage of cells expressing both of the H-2 molecules H-2Kb and H-2Db to over 90 in each case. With the high level of expression of the H-2Kb and H-2Db antigens, these cell lines should be sensitive to lysis by heterogeneous cultures of CTL if the truncated T antigen is expressed on the cell surfaces. The same cell lines were treated with gamma interferon and assayed for sensitivity to lysis by CTL clones Kll and K19 and by B6/WT-19 immune lymphocytes, prepared as described above, in a 51Cr release assay (Table 5) . Gamma interferon-treated and untreated B6/WT-19 cells were sensitive to lysis by all the effectors, while B6/PY cells were not susceptible to lysis. ""he cell lines B6/RL75-RL12 and B6/RL75-RL115 were sensitive to lysis by bulk-culture anti-SV40 immune lymphocytes only after treatment with gamma interferon. Gamma interferon-treated and untreated B6/RL75-RL12 and B6/RL75-RL115 cells were not sensitive to lysis by the CTL clones Kll Fig.   7 .
DISCUSSION
The SV40 tumor-specific transplantation antigen, although described in 1963 (10, 24, 33, 36) Later studies using T antigen purified to homogeneity led to the conclusion that the antigenicity for tumor-specific transplantation antigen resides in T antigen (9, 58) . A similar conclusion was also reached by using SV40 T antigen fragments produced by the adenovirus type 2-SV40 hybrid viruses (30) . Several additional lines of evidence indicated that T antigen is the target protein for the CTL that recognize SV40 tumor-specific transplantation antigen in association with MHC class I antigens. Purified T antigen could prime mice for the generation of SV40-specific CTL (8, 58) . In addition, immunogenetic evidence demonstrated that T antigen is reprocessed in vivo by antigen-presenting cells. SV40-transformed allogeneic and xenogeneic cells induce the generation of pre-CTL, which can be stimulated in vitro only with SV40-transformed cells which share H-2 class I antigens with the pre-CTL (19) . Finally, the reactivity of a single SV40-specific H-2Kb-restricted CTL clone can be abrogated by a monoclonal antibody directed to the T antigen (41) . However, the precise region of SV40 T antigen to which either the CTL clone or the monoclonal antibody is directed was not determined.
We have previously demonstrated that CTL-reactive sites are located in the amino-terminal region of the T antigen, since a cell line synthesizing SV40 T antigen of 1 to 271 amino acids is susceptible to CTL generated in response to transformed cells synthesizing wild-type T antigen (61) . These studies were later confirmed and extended, demonstrating that the CTL-reactive sites also were located in the carboxy-terminal region of the molecule (21 (6) . For mapping studies, the restriction elements, either H-2Kb or H-2Db, must be expressed in sufficient quantities to provide self-recognition. This requirement was evident from our results with cell lines missing amino acid residues 189 to 223 or 189 to 228. These cell lines did not express sufficient amounts of H-2Db to be lysed by SV40 CTL clones Kll and K19 or by SV40 CTL generated in bulk culture. Treatment of the cell lines with gamma interferon restored H-2 expression, and the cells became susceptible to SV40 CTL generated in bulk culture but not to clones Kll and K19. The requirement for corecognition of the MHC class I antigens and the antigenic site by antigen-specific CTL may be partly responsible for the limited number of antigenic sites recognized by CTL. Since the T-cell receptor must recognize class I antigens in association with an antigen site on the T antigen, the residues which become accessible to the T-cell receptor may be limited. The site on SV40 T antigen that associates with MHC class I antigen is not yet known.
Since there are no known stretches of hydrophobic residues in the SV40 T antigen to explain its presence in the cell membranes, Sharma et al. (49) have proposed that T antigen is not transported to the cell membranes by an exocytotic pathway. Regardless of the mechanism, SV40 T antigen is present in the intact form in the plasma membranes. Both carboxy-and amino-terminal ends of cell surface T antigen are accessible to binding by SV40-specific monoclonal antibodies (3, 13, 20, 48, 68) , and the T antigen can be immunoprecipitated intact from the plasma membrane (46, 48, 51, 
52, 59
). There is evidence that cell surface T antigen is acylated (34) and glycosylated (29) . T antigen is not the only nuclear protein that is recognized by CTL in the plasma membrane. The nucleoprotein (NP) of influenza virus is also recognized by antiviral MHC class II-restricted CTL (63, 64, 66, 70) . In addition, influenza virus polymerases and a nonstructural protein have been shown to provide a target for CTL (4, 5) . Townsend et al. (65) have suggested that the influenza virus NP is proteolytically processed and expressed on the infected-cell surface, much as an antigenpresenting cell would process and express antigen. In support of this notion, short stretches of synthetic peptides corresponding to regions of influenza virus NP, when adsorbed to cells provide a target for NP-specific CTL (63) .
However, these investigators were not able to detect any effect of chloroquine, an agent that raises lysosomal pH and inhibits the lysosomal degradation of protein, on the susceptibility of virus-infected or NP-gene-transfected cells to lysis by NP-specific CTL. Therefore, proteolytic processing of the target antigen must occur in a nonlysosomal compartment of the target cell. 
